(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.

  title={(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.},
  author={Joseph Knoll},
  journal={Pharmacology \& toxicology},
  volume={82 2},
  • J. Knoll
  • Published 1 February 1998
  • Biology, Psychology
  • Pharmacology & toxicology
beta-Phenylethylamine and its long acting derivatives, the amphetamines, are mixed-acting stimulants of the sympathetic system in the brain. They enhance the impulse propagation mediated release of catecholamines (catecholaminergic activity enhancer effect) and displace catecholamines from their stores (catecholamine releasing effect). (-)Deprenyl (selegiline), a close structural relative to (-)methamphetamine, is the first catecholaminergic activity enhancer substance in clinical use devoid of… 
The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
  • P. Gaszner, I. Miklya
  • Biology, Chemistry
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology
  • 2004
The evaluation of the special pharmacological profile of the synthetic mesencephalic enhancer substance, especially the high potency and the unusual safety and tolerability of (-)-BPAP provide hope that this compound may in the future significantly improve the effectiveness of drug therapy in major depression and its combination with uptake inhibitors may substantially diminish the number of therapy resistant cases.
Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
  • I. Miklya
  • Medicine, Biology
    Pharmacological reports : PR
  • 2014


The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
  • J. Knoll
  • Biology
    Journal of neural transmission. Supplementum
  • 1993
Male rats maintained on (-)deprenyl live longer, lose their capacity to ejaculate later, show improved performance in learning tests and maintain this activity for a longer period than their untreated peers, as a consequence of its complex spectrum of activity.
Pharmacological basis of the therapeutic effect of (−)deprenyl in age‐related neurological diseases
  • J. Knoll
  • Biology
    Medicinal research reviews
  • 1992
It is concluded that in Parkinson's disease and Alzheimer's disease patients need to be treated daily with 10 mg (-)deprenyl from diagnosis until death, irrespective of other medication.
Preclinical Evaluation of l-Deprenyl: Lack of Amphetamine-Like Abuse Potential
Evaluation of l-deprenyl for cocaine-like abuse liability is a relevant topic of research because the reinforcing effects of cocaine may be mediated by inhibition of dopamine reuptake, and l-Deprenyl, in addition to its MAO-B actions, also inhibits dopamine reptake.
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.
Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity
The findings showed that 6-OHDA caused a reduction of TH immunoreactivity and catecholamine histofluorescence in neuronal somata, as well as a decrease in the number and length of adrenergic nerve fibers in the submandibular gland.